221 related articles for article (PubMed ID: 27764892)
21. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease.
Sookoian S; Castaño GO; Burgueño AL; Rosselli MS; Gianotti TF; Mallardi P; Martino JS; Pirola CJ
Atherosclerosis; 2010 Apr; 209(2):585-91. PubMed ID: 19896127
[TBL] [Abstract][Full Text] [Related]
22. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
23. Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response.
Spruss A; Henkel J; Kanuri G; Blank D; Püschel GP; Bischoff SC; Bergheim I
Mol Med; 2012 Dec; 18(1):1346-55. PubMed ID: 22952059
[TBL] [Abstract][Full Text] [Related]
24. Liver fat deposition and mitochondrial dysfunction in morbid obesity: An approach combining metabolomics with liver imaging and histology.
Calvo N; Beltrán-Debón R; Rodríguez-Gallego E; Hernández-Aguilera A; Guirro M; Mariné-Casadó R; Millá L; Alegret JM; Sabench F; del Castillo D; Vinaixa M; Rodríguez MÀ; Correig X; García-Álvarez R; Menendez JA; Camps J; Joven J
World J Gastroenterol; 2015 Jun; 21(24):7529-44. PubMed ID: 26140000
[TBL] [Abstract][Full Text] [Related]
25. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA.
Campbell PT; VanWagner LB; Colangelo LA; Lewis CE; Henkel A; Ajmera VH; Lloyd-Jones DM; Vaughan DE; Khan SS
Liver Int; 2020 May; 40(5):1111-1120. PubMed ID: 32090434
[TBL] [Abstract][Full Text] [Related]
26. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
Jamali R; Razavizade M; Arj A; Aarabi MH
World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
[TBL] [Abstract][Full Text] [Related]
27. Role of γ-glutamyl transferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease.
Kasapoglu B; Turkay C; Yalcın KS; Carlioglu A; Koktener A
Indian J Med Res; 2016 Jan; 143(1):30-6. PubMed ID: 26997011
[TBL] [Abstract][Full Text] [Related]
28. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Alessi MC; Bastelica D; Mavri A; Morange P; Berthet B; Grino M; Juhan-Vague I
Arterioscler Thromb Vasc Biol; 2003 Jul; 23(7):1262-8. PubMed ID: 12750120
[TBL] [Abstract][Full Text] [Related]
29. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
30. β-Klotho gene variation is associated with liver damage in children with NAFLD.
Dongiovanni P; Crudele A; Panera N; Romito I; Meroni M; De Stefanis C; Palma A; Comparcola D; Fracanzani AL; Miele L; Valenti L; Nobili V; Alisi A
J Hepatol; 2020 Mar; 72(3):411-419. PubMed ID: 31655133
[TBL] [Abstract][Full Text] [Related]
31. The Relationship between the Growth Hormone/Insulin-like Growth Factor System and the Histological Features of Nonalcoholic Fatty Liver Disease.
Chishima S; Kogiso T; Matsushita N; Hashimoto E; Tokushige K
Intern Med; 2017; 56(5):473-480. PubMed ID: 28250290
[TBL] [Abstract][Full Text] [Related]
32. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
[TBL] [Abstract][Full Text] [Related]
33. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
[TBL] [Abstract][Full Text] [Related]
34. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial.
Polyzos SA; Kountouras J; Mantzoros CS; Polymerou V; Katsinelos P
Diabetes Obes Metab; 2017 Dec; 19(12):1805-1809. PubMed ID: 28452101
[TBL] [Abstract][Full Text] [Related]
35. PAI-1, obesity, insulin resistance and risk of cardiovascular events.
Juhan-Vague I; Alessi MC
Thromb Haemost; 1997 Jul; 78(1):656-60. PubMed ID: 9198234
[TBL] [Abstract][Full Text] [Related]
36. Plasma cathepsin D levels: a novel tool to predict pediatric hepatic inflammation.
Walenbergh SM; Houben T; Hendrikx T; Jeurissen ML; van Gorp PJ; Vreugdenhil AC; Adriaanse MP; Buurman WA; Hofker MH; Mosca A; Lindsey PJ; Alisi A; Liccardo D; Panera N; Koek GH; Nobili V; Shiri-Sverdlov R
Am J Gastroenterol; 2015 Mar; 110(3):462-70. PubMed ID: 25732418
[TBL] [Abstract][Full Text] [Related]
37. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
Bedossa P; Patel K
Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
[TBL] [Abstract][Full Text] [Related]
38. Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity.
Wolfs MG; Gruben N; Rensen SS; Verdam FJ; Greve JW; Driessen A; Wijmenga C; Buurman WA; Franke L; Scheja L; Koonen DP; Shiri-Sverdlov R; van Haeften TW; Hofker MH; Fu J
Nutr Diabetes; 2015 Feb; 5(2):e146. PubMed ID: 25664838
[TBL] [Abstract][Full Text] [Related]
39. Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease.
Eriksen PL; Thomsen KL; Sørensen M; Vilstrup H; Hvas AM
Thromb Res; 2022 May; 213():9-15. PubMed ID: 35256195
[TBL] [Abstract][Full Text] [Related]
40. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease.
Nobili V; Manco M; Ciampalini P; Diciommo V; Devito R; Piemonte F; Comparcola D; Guidi R; Marcellini M
Eur J Endocrinol; 2006 Nov; 155(5):735-43. PubMed ID: 17062890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
